These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 18722004

  • 1. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER.
    Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Endoscopic screening for gastric cancer.
    Dan YY, So JB, Yeoh KG.
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Screening for renal cancer in recipients of kidney transplants.
    Wong G, Howard K, Webster AC, Chapman JR, Craig JC.
    Nephrol Dial Transplant; 2011 May; 26(5):1729-39. PubMed ID: 20961889
    [Abstract] [Full Text] [Related]

  • 16. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness analysis of anal cancer screening in HIV-positive women.
    Lazenby GB, Unal ER, Andrews AL, Simpson K.
    J Low Genit Tract Dis; 2012 Jul; 16(3):275-80. PubMed ID: 22227844
    [Abstract] [Full Text] [Related]

  • 18. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
    Yang KC, Liao CS, Chiu YH, Yen AM, Chen TH.
    J Med Screen; 2006 Jul; 13 Suppl 1():S8-13. PubMed ID: 17227635
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS, Liao CS, Chang SH, Lai HC, Chen TH.
    J Med Screen; 2007 Jul; 14(4):191-9. PubMed ID: 18078564
    [Abstract] [Full Text] [Related]

  • 20. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A, Hessabi HK, Gorenoi V, Schönermark MP.
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.